Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Cacquevel, Matthias ^a   Aeschbach, Lorène ^a   Houacine, Jemila ^a   Fraering, Patrick C ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; EMBRYO; ENZYME ACTIVITY; FAMILIAL ALZHEIMER DISEASE; FIBROBLAST; GENE MUTATION; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE; ENZYME ACTIVATION; FIBROBLASTS; GENE EXPRESSION; HUMANS; MICE; MUTATION; PHENOTYPE; PRESENILIN-1;

EID: 84860015622     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035133     Document Type: Article

References (61)

1. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376: 775-778.
2. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760.
3. Weihofen A, Martoglio B, (2003) Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. Trends Cell Biol 13: 71-78.
4. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, et al. (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2: 428-434.
5. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, et al. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398: 513-517.
6. Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ, (2000) The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J Biol Chem 275: 3173-3178.
7. Beel AJ, Sanders CR, (2008) Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 65: 1311-1334.
8. Bot N, Schweizer C, Ben Halima S, Fraering PC, (2010) Processing of the synaptic cell-adhesion molecule neurexin-3{beta} by Alzheimer's disease {alpha}- and {gamma}-secretases. J Biol Chem.
9. Parks AL, Curtis D, (2007) Presenilin diversifies its portfolio. Trends Genet 23: 140-150.
10. Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, et al. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci 25: 436-445.
11. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, et al. (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56: 66-78.
12. Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, et al. (2006) TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440: 1208-1212.
13. He G, Luo W, Li P, Remmers C, Netzer WJ, et al. (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467: 95-98.
14. Wakabayashi T, De Strooper B, (2008) Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) 23: 194-204.
15. Citron M, Westaway D, Xia W, Carlson G, Diehl T, et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72.
16. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, et al. (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59: 398-407.
17. Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, et al. (1998) Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 43: 256-258.
18. Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, et al. (1999) Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci Lett 265: 61-63.
19. Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, et al. (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci 20: 8717-8726.
20. Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, et al. (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A 99: 8025-8030.
21. Qi Y, Morishima-Kawashima M, Sato T, Mitsumori R, Ihara Y, (2003) Distinct mechanisms by mutant presenilin 1 and 2 leading to increased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells. Biochemistry 42: 1042-1052.
22. Dowjat WK, Kuchna I, Wisniewski T, Wegiel J, (2004) A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. J Alzheimers Dis 6: 31-43.
23. Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, et al. (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96: 732-742.
24. Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, et al. (2009) gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324: 639-642.
25. Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, et al. (2003) Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem 278: 24277-24284.
26. Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, et al. (2004) Purification and characterization of the human gamma-secretase complex. Biochemistry 43: 9774-9789.
27. Cacquevel M, Aeschbach L, Osenkowski P, Li D, Ye W, et al. (2008) Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J Neurochem 104: 210-220.
28. Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, et al. (2006) Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci U S A 103: 6889-6894.
29. Osenkowski P, Li H, Ye W, Li D, Aeschbach L, et al. (2009) Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol 385: 642-652.
30. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, et al. (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A 96: 11872-11877.
31. Herreman A, Van Gassen G, Bentahir M, Nyabi O, Craessaerts K, et al. (2003) gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J Cell Sci 116: 1127-1136.
32. Nyabi O, Bentahir M, Horre K, Herreman A, Gottardi-Littell N, et al. (2003) Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and Nicastrin glycosylation but remain catalytically inactive in the absence of wild type Presenilin. J Biol Chem 278: 43430-43436.
33. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, et al. (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17: 181-190.
34. Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, et al. (2007) Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest 117: 1230-1239.
35. Heilig EA, Xia W, Shen J, Kelleher RJ, (2010) A presenilin-1 mutation identified in familial Alzheimer's disease with cotton wool plaques causes nearly complete loss of {gamma}-secretase activity. J Biol Chem.
36. Lichtenthaler SF, Multhaup G, Masters CL, Beyreuther K, (1999) A novel substrate for analyzing Alzheimer's disease gamma-secretase. FEBS letters 453: 288-292.
37. Fraering PC, LaVoie MJ, Ye W, Ostaszewski BL, Kimberly WT, et al. (2004) Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry 43: 323-333.
38. Duff K, Eckman C, Zehr C, Yu X, Prada CM, et al. (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710-713.
39. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, et al. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 45-53.
40. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, et al. (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 267: 546-554.
41. Jan A, Gokce O, Luthi-Carter R, Lashuel HA, (2008) The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem 283: 28176-28189.
42. Jarrett JT, Berger EP, Lansbury PT Jr, (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697.
43. Scheuner D, Eckman C, Jensen M, Song X, Citron M, et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870.
44. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97-100.
45. Borchelt DR, Lee MK, Gonzales V, Slunt HH, Ratovitski T, et al. (2002) Accumulation of proteolytic fragments of mutant presenilin 1 and accelerated amyloid deposition are co-regulated in transgenic mice. Neurobiol Aging 23: 171-177.
46. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, et al. (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7: 940-946.
47. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, et al. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360: 672-674.
48. Haass C, Lemere CA, Capell A, Citron M, Seubert P, et al. (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1: 1291-1296.
49. Munter LM, Botev A, Richter L, Hildebrand PW, Althoff V, et al. (2010) Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif. J Biol Chem 285: 21636-21643.
50. Citron M, Eckman CB, Diehl TS, Corcoran C, Ostaszewski BL, et al. (1998) Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis 5: 107-116.
51. Dumanchin C, Tournier I, Martin C, Didic M, Belliard S, et al. (2006) Biological effects of four PSEN1 gene mutations causing Alzheimer disease with spastic paraparesis and cotton wool plaques. Hum Mutat 27: 1063.
52. Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, et al. (2006) Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 27: 686-695.
53. Steiner H, Romig H, Grim MG, Philipp U, Pesold B, et al. (1999) The biological and pathological function of the presenilin-1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing. J Biol Chem 274: 7615-7618.
54. Houlden H, Baker M, McGowan E, Lewis P, Hutton M, et al. (2000) Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol 48: 806-808.
55. Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, et al. (2005) Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 46: 541-554.
56. Veeraraghavalu K, Choi SH, Zhang X, Sisodia SS, (2010) Presenilin 1 mutants impair the self-renewal and differentiation of adult murine subventricular zone-neuronal progenitors via cell-autonomous mechanisms involving notch signaling. J Neurosci 30: 6903-6915.
57. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, et al. (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42: 23-36.
58. Wolfe MS, (2012) gamma-Secretase inhibitors and modulators for Alzheimer's disease. Journal of neurochemistry 120 (Suppl 1): 89-98.
59. Schor NF, (2011) What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Annals of neurology 69: 237-239.
60. Xu X, (2009) Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. Journal of Alzheimer's disease: JAD 16: 211-224.
61. Salmon P, Trono D, (2007) Production and titration of lentiviral vectors. Curr Protoc Hum Genet Chapter 12: Unit 12 10.